Holen Sie sich die Stockscreener-App
9.49
4.04%
-0.40
Schlusskurs vom Vortag:
$9.89
Offen:
$9.85
24-Stunden-Volumen:
1.19M
Relative Volume:
0.58
Marktkapitalisierung:
$695.33M
Einnahmen:
$31,000
Nettoeinkommen (Verlust:
$-54.42M
KGV:
-9.7055
EPS:
-0.9778
Netto-Cashflow:
$-48.99M
1W Leistung:
-3.46%
1M Leistung:
+13.65%
6M Leistung:
+66.20%
1J Leistung:
+54.31%
1-Tages-Spanne:
$9.215
$9.86
1-Wochen-Bereich:
$9.215
$10.45
52-Wochen-Spanne:
$4.35
$11.36
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
9.49 | 695.33M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 8, 2026 - marketscreener.com
Form 4 Candel Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
[Form 4] Candel Therapeutics, Inc. Insider Trading Activity - Stock Titan
Candel Therapeutics (CADL) Chief Commercial Officer Sims listed in Form 3 - Stock Titan
Candel hands its new commercial chief 285,000 options - Stock Titan
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
Insider Sell: Francesca Barone Sells Shares of Candel Therapeuti - GuruFocus
Candel Therapeutics CSO Francesca Barone sells $235k in stock By Investing.com - Investing.com Australia
Candel Therapeutics CSO Francesca Barone sells $235k in stock - Investing.com
Form 4 Candel Therapeutics Inc For: 1 July By Investing.com - Investing.com UK
Candel Therapeutics (CADL) CSO executes 23,447-share open-market sale under 10b5-1 plan - Stock Titan
Candel Therapeutics (CADL) CTO sells 7,000 shares in planned trade - Stock Titan
Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options - Stock Titan
Candel Therapeutics (CADL) director receives fully vested option award - Stock Titan
Candel Therapeutics (CADL) director receives fully vested 381-option equity grant - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel grants new employee 25,000 stock options at $10.30 - Stock Titan
Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com - Investing.com South Africa
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’ - TradingView
Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug - marketscreener.com
Candel Therapeutics initiates phase 3 lung cancer trial - Investing.com
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - The Manila Times
Candel opens global phase 3 AURORA trial in lung cancer - Stock Titan
[144] Candel Therapeutics, Inc. SEC Filing - Stock Titan
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Price to sales forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Enterprise value to EBITDA forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Candel Therapeutics, Inc. Actuals & Estimates (NASDAQ:CADL) - TradingView
Enterprise value to EBITDA forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
Enterprise value to revenue forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Enterprise value to EBIT forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Price to earnings forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Candel Therapeutics, Inc. Actuals & Estimates (BOATS:CADL) - TradingView
Price to earnings forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
Enterprise value to revenue forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
$Candel Therapeutics (CADL.US)$ [Fireworks]New 52 Week High[Fireworks] 9.75 [Twirl][Twirl][Twirl] - Moomoo
CADL Forecast — Price Target — Prediction for 2027 - TradingView
Candel Therapeutics Designates Mark Sims as CCO - Yahoo Finance
Candel Therapeutics names Mark Sims as chief commercial officer By Investing.com - Investing.com Australia
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Ahead of Planned BLA Filing - citybiz
Candel Therapeutics names Mark Sims as chief commercial officer - Investing.com
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - The Manila Times
Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 - marketscreener.com
Candel Therapeutics, Inc. Files Form 8-K with SEC Detailing Corporate Information and Emerging Growth Status - Minichart
Candel Therapeutics Stockholders Approve Directors and Auditor - TipRanks
Form 4 Candel Therapeutics Inc For: 24 June By Investing.com - Investing.com South Africa
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):